Objective: To evaluate the safety and efficacy of combining deferiprone(DFP)and deferoxamine(DFO)in iron chelation therapy in patients with thalassemia.
探讨酮(DFP)和
(DFO)联
用药对
症地中海贫
治疗的安全性和有效性。
声明:以上例句、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
The following year, Vertex and Crispr Therapeutics, pharmaceutical companies based in Boston, Massachusetts, and Zug, Switzerland, said they would co-develop a treatment named CTX001, a treatment for two disorders: sickle-cell disease and beta thalassemia.
次年,总部位于马萨诸塞州波士顿的制药公司Vertex和总部位于瑞士楚格的Crispr Therapeutics表示,他们将共同开发一种名为CTX001的治疗方法,用于治疗镰状细胞病和β中海贫
。